Starling Oncology Institute Inc (STLN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2023 | 09-2023 | 06-2023 | 03-2023 | 12-2022 | |
| Sales | 85,788 | 82,035 | 80,224 | 76,192 | 71,424 |
| Cost of Goods | 71,409 | 66,057 | 65,107 | 62,093 | 55,795 |
| Gross Profit | 14,379 | 15,978 | 15,117 | 14,099 | 15,629 |
| Operating Expenses | 30,076 | 29,960 | 30,162 | 47,059 | 41,503 |
| Operating Income | -15,288 | -13,925 | -14,938 | -32,867 | -25,079 |
| Interest Expense | 1,941 | 1,755 | 1,638 | 1,443 | 2,450 |
| Other Income | -1,839 | -1,604 | -222 | 4,356 | 16,155 |
| Pre-tax Income | -19,068 | -17,284 | -16,798 | -29,954 | -11,374 |
| Income Tax | -314 | 135 | 99 | 44 | -367 |
| Net Income Continuous | -18,754 | -17,419 | -16,897 | -29,998 | -11,007 |
| Net Income | $-18,754 | $-17,419 | $-16,897 | $-29,998 | $-11,007 |
| EPS Basic Total Ops | -0.21 | -0.19 | -0.19 | -0.33 | -0.13 |
| EPS Basic Continuous Ops | -0.25 | -0.24 | -0.23 | -0.41 | -0.15 |
| EPS Diluted Total Ops | -0.21 | -0.19 | -0.19 | -0.33 | -0.19 |
| EPS Diluted Continuous Ops | -0.25 | -0.24 | -0.23 | -0.41 | -0.14 |
| EBITDA(a) | $-14,058 | $-9,784 | $-12,734 | $-14,128 | $-13,382 |